| Name | Title | Contact Details |
|---|
SCA`s vision is to be the partner of choice for physicians, hospitals, and health systems in developing and operating ambulatory surgery centers and surgical hospitals across the country and in enhancing hospital-based surgical departments. SCA owns and/or provides management services to 210 ambulatory surgery centers, surgical hospitals, and hospital surgery departments, in partnership with approximately 7,500 physicians and in affiliation with 110 health systems. SCA`s clinical systems, service line growth strategies, benchmarking processes, and efficiency programs create measurable advantage for surgical facilities – clinically, operationally, and financially.
RxAlly was developed to provide a new solution to the critical issues of providing additional access to care and ensuring effective health care spending at a time when prescription medicine misuse is associated with $290 billion in annual costs. The RxAlly network of pharmacies aims to improve patient health through enhanced pharmacist care that combines clinical research, evidence-based clinical services and an interoperable technology platform.
Synergy Vision is a Livermore, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Amicus Therapeutics, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Amicus Therapeutics, Inc. is based in Cranbury, NJ. You can find more information on Amicus Therapeutics, Inc. at www.amicustherapeutics.com
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.